Human coagulation factor VIII is indicated for the treatment and prevention of bleeding in patients with hemophilia A, including during acute bleeding episodes and surgical procedures. Its key advantage is rapid and direct replacement of the missing clotting factor, allowing effective restoration of normal coagulation and fast control of bleeding. In hospital settings, intravenous administration ensures immediate availability and precise dosing, which is critical in emergency situations such as trauma or major surgery. It is also used for prophylaxis to reduce the frequency of spontaneous bleeding and prevent long-term joint damage. Reliable efficacy, predictable response, and the ability to tailor dosing make factor VIII an essential and life-saving therapy in hemophilia management.